HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation.


Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
03 2020
Historique:
received: 18 11 2019
accepted: 29 01 2020
pubmed: 7 2 2020
medline: 2 6 2020
entrez: 7 2 2020
Statut: ppublish

Résumé

The anti-cancer drug target poly(ADP-ribose) polymerase 1 (PARP1) and its close homologue, PARP2, are early responders to DNA damage in human cells

Identifiants

pubmed: 32028527
doi: 10.1038/s41586-020-2013-6
pii: 10.1038/s41586-020-2013-6
pmc: PMC7104379
mid: EMS85649
doi:

Substances chimiques

Carrier Proteins 0
HPF1 protein, human 0
Nuclear Proteins 0
Poly(ADP-ribose) Polymerase Inhibitors 0
NAD 0U46U6E8UK
PARP1 protein, human EC 2.4.2.30
PARP2 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30
Poly(ADP-ribose) Polymerases EC 2.4.2.30

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

598-602

Subventions

Organisme : Medical Research Council
ID : MC_U105178934
Pays : United Kingdom
Organisme : Cancer Research UK
ID : A22284
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 210634
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 101794
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_U117533887
Pays : United Kingdom

Commentaires et corrections

Type : CommentIn

Références

Gupte, R., Liu, Z. & Kraus, W. L. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 31, 101–126 (2017).
pubmed: 28202539 pmcid: 5322727 doi: 10.1101/gad.291518.116
Pascal, J. M. The comings and goings of PARP-1 in response to DNA damage. DNA Repair 71, 177–182 (2018).
pubmed: 30177435 pmcid: 6637744 doi: 10.1016/j.dnarep.2018.08.022
Martin-Hernandez, K., Rodriguez-Vargas, J. M., Schreiber, V. & Dantzer, F. Expanding functions of ADP-ribosylation in the maintenance of genome integrity. Semin. Cell Dev. Biol. 63, 92–101 (2017).
pubmed: 27670719 doi: 10.1016/j.semcdb.2016.09.009
Liu, C., Vyas, A., Kassab, M. A., Singh, A. K. & Yu, X. The role of poly ADP-ribosylation in the first wave of DNA damage response. Nucleic Acids Res. 45, 8129–8141 (2017).
pubmed: 28854736 pmcid: 5737498 doi: 10.1093/nar/gkx565
Gibbs-Seymour, I., Fontana, P., Rack, J. G. M. & Ahel, I. HPF1/C4orf27 is a PARP-1-interacting protein that regulates PARP-1 ADP-ribosylation activity. Mol. Cell 62, 432–442 (2016).
pubmed: 27067600 pmcid: 4858568 doi: 10.1016/j.molcel.2016.03.008
Leidecker, O. et al. Serine is a new target residue for endogenous ADP-ribosylation on histones. Nat. Chem. Biol. 12, 998–1000 (2016).
pubmed: 27723750 pmcid: 5113755 doi: 10.1038/nchembio.2180
Bonfiglio, J. J. et al. Serine ADP-ribosylation depends on HPF1. Mol. Cell 65, 932–940 (2017).
pubmed: 28190768 pmcid: 5344681 doi: 10.1016/j.molcel.2017.01.003
Palazzo, L. et al. Serine is the major residue for ADP-ribosylation upon DNA damage. eLife 7, e34334 (2018).
pubmed: 29480802 pmcid: 5837557 doi: 10.7554/eLife.34334
Crawford, K., Bonfiglio, J. J., Mikoč, A., Matic, I. & Ahel, I. Specificity of reversible ADP-ribosylation and regulation of cellular processes. Crit. Rev. Biochem. Mol. Biol. 53, 64–82 (2018).
pubmed: 29098880 doi: 10.1080/10409238.2017.1394265
Larsen, S. C., Hendriks, I. A., Lyon, D., Jensen, L. J. & Nielsen, M. L. Systems-wide analysis of serine ADP-ribosylation reveals widespread occurrence and site-specific overlap with phosphorylation. Cell Rep. 24, 2493–2505 (2018).
pubmed: 30157440 doi: 10.1016/j.celrep.2018.07.083
Fontana, P. et al. Serine ADP-ribosylation reversal by the hydrolase ARH3. eLife 6, e28533 (2017).
pubmed: 28650317 pmcid: 5552275 doi: 10.7554/eLife.28533
Langelier, M. F., Planck, J. L., Roy, S. & Pascal, J. M. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science 336, 728–732 (2012).
pubmed: 22582261 pmcid: 3532513 doi: 10.1126/science.1216338
Langelier, M. F., Riccio, A. A. & Pascal, J. M. PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1. Nucleic Acids Res. 42, 7762–7775 (2014).
pubmed: 24928857 pmcid: 4081085 doi: 10.1093/nar/gku474
Dawicki-McKenna, J. M. et al. PARP-1 activation requires local unfolding of an autoinhibitory domain. Mol. Cell 60, 755–768 (2015).
pubmed: 26626480 pmcid: 4712911 doi: 10.1016/j.molcel.2015.10.013
Langelier, M. F., Eisemann, T., Riccio, A. A. & Pascal, J. M. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr. Opin. Struct. Biol. 53, 187–198 (2018).
pubmed: 30481609 pmcid: 6687463 doi: 10.1016/j.sbi.2018.11.002
Langelier, M. F., Zandarashvili, L., Aguiar, P. M., Black, B. E. & Pascal, J. M. NAD
pubmed: 29487285 pmcid: 5829251 doi: 10.1038/s41467-018-03234-8
Amé, J. C., Spenlehauer, C. & de Murcia, G. The PARP superfamily. BioEssays 26, 882–893 (2004).
pubmed: 15273990 doi: 10.1002/bies.20085
Marsischky, G. T., Wilson, B. A. & Collier, R. J. Role of glutamic acid 988 of human poly-ADP-ribose polymerase in polymer formation. Evidence for active site similarities to the ADP-ribosylating toxins. J. Biol. Chem. 270, 3247–3254 (1995).
pubmed: 7852410 doi: 10.1074/jbc.270.7.3247
Ruf, A., de Murcia, G. & Schulz, G. E. Inhibitor and NAD
pubmed: 9521710 doi: 10.1021/bi972383s
Bell, C. E. & Eisenberg, D. Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry 35, 1137–1149 (1996).
pubmed: 8573568 doi: 10.1021/bi9520848
Ruf, A., Mennissier de Murcia, J., de Murcia, G. & Schulz, G. E. Structure of the catalytic fragment of poly(AD-ribose) polymerase from chicken. Proc. Natl Acad. Sci. USA 93, 7481–7485 (1996).
pubmed: 8755499 pmcid: 38770 doi: 10.1073/pnas.93.15.7481
Kleine, H. et al. Substrate-assisted catalysis by PARP10 limits its activity to mono-ADP-ribosylation. Mol. Cell 32, 57–69 (2008).
pubmed: 18851833 doi: 10.1016/j.molcel.2008.08.009
Laing, S., Unger, M., Koch-Nolte, F. & Haag, F. ADP-ribosylation of arginine. Amino Acids 41, 257–269 (2011).
pubmed: 20652610 doi: 10.1007/s00726-010-0676-2
Zhang, R. G. et al. The three-dimensional crystal structure of cholera toxin. J. Mol. Biol. 251, 563–573 (1995).
pubmed: 7658473 doi: 10.1006/jmbi.1995.0456
Hendriks, I. A., Larsen, S. C. & Nielsen, M. L. An advanced strategy for comprehensive profiling of ADP-ribosylation sites using mass spectrometry-based proteomics. MCP 18, 1010–1026 (2019).
pubmed: 30798302 pmcid: 6495254
Ahmadian, M. R., Stege, P., Scheffzek, K. & Wittinghofer, A. Confirmation of the arginine-finger hypothesis for the GAP-stimulated GTP-hydrolysis reaction of Ras. Nat. Struct. Biol. 4, 686–689 (1997).
pubmed: 9302992 doi: 10.1038/nsb0997-686
Rack, J. G. M. et al. (ADP-ribosyl)hydrolases: structural basis for differential substrate recognition and inhibition. Cell Chem. Biol. 25, 1533–1546 (2018).
pubmed: 30472116 pmcid: 6309922 doi: 10.1016/j.chembiol.2018.11.001
Wang, M. et al. Structure-function analyses reveal the mechanism of the ARH3-dependent hydrolysis of ADP-ribosylation. J. Biol. Chem. 293, 14470–14480 (2018).
pubmed: 30045870 pmcid: 6139573 doi: 10.1074/jbc.RA118.004284
Pourfarjam, Y. et al. Structure of human ADP-ribosyl-acceptor hydrolase 3 bound to ADP-ribose reveals a conformational switch that enables specific substrate recognition. J. Biol. Chem. 293, 12350–12359 (2018).
pubmed: 29907568 pmcid: 6093245 doi: 10.1074/jbc.RA118.003586
Langelier, M. F., Planck, J. L., Servent, K. M. & Pascal, J. M. Purification of human PARP-1 and PARP-1 domains from Escherichia coli for structural and biochemical analysis. Methods Mol. Biol. 780, 209–226 (2011).
pubmed: 21870263 doi: 10.1007/978-1-61779-270-0_13
Chae, Y.-K. Recommendations for the selective labeling of [
Tong, K. I., Yamamoto, M. & Tanaka, T. A simple method for amino acid selective isotope labeling of recombinant proteins in E. coli. J. Biomol. NMR 42, 59–67 (2008).
pubmed: 18762866 doi: 10.1007/s10858-008-9264-0
Marley, J., Lu, M. & Bracken, C. A method for efficient isotopic labeling of recombinant proteins. J. Biomol. NMR 20, 71–75 (2001).
pubmed: 11430757 doi: 10.1023/A:1011254402785
Kabsch, W. Xds. Acta Crystallogr. D 66, 125–132 (2010).
pubmed: 20124692 pmcid: 2815665 doi: 10.1107/S0907444909047337
Evans, P. Scaling and assessment of data quality. Acta Crystallogr. D 62, 72–82 (2006).
pubmed: 16369096 doi: 10.1107/S0907444905036693
Terwilliger, T. C. et al. Decision-making in structure solution using Bayesian estimates of map quality: the PHENIX AutoSol wizard. Acta Crystallogr. D 65, 582–601 (2009).
pubmed: 19465773 pmcid: 2685735 doi: 10.1107/S0907444909012098
Terwilliger, T. C. & Berendzen, J. Automated MAD and MIR structure solution. Acta Crystallogr. D 55, 849–861 (1999).
pubmed: 10089316 pmcid: 2746121 doi: 10.1107/S0907444999000839
Winter, G. xia2: an expert system for macromolecular crystallography data reduction. J. Appl. Crystallogr. 43, 186–190 (2010).
doi: 10.1107/S0021889809045701
Storoni, L. C., McCoy, A. J. & Read, R. J. Likelihood-enhanced fast rotation functions. Acta Crystallogr. D 60, 432–438 (2004).
pubmed: 14993666 doi: 10.1107/S0907444903028956
Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D 60, 2126–2132 (2004).
pubmed: 15572765 doi: 10.1107/S0907444904019158
Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D 53, 240–255 (1997).
pubmed: 15299926 doi: 10.1107/S0907444996012255
Afonine, P. V. et al. Joint X-ray and neutron refinement with phenix.refine. Acta Crystallogr. D 66, 1153–1163 (2010).
pubmed: 21041930 pmcid: 2967420 doi: 10.1107/S0907444910026582
Afonine, P. V. et al. FEM: feature-enhanced map. Acta Crystallogr. D 71, 646–666 (2015).
pubmed: 25760612 pmcid: 4356370 doi: 10.1107/S1399004714028132
Ashkenazy, H. et al. ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 44, W344-50 (2016).
pubmed: 27166375 pmcid: 4987940 doi: 10.1093/nar/gkw408
Katoh, K., Rozewicki, J. & Yamada, K. D. MAFFT online service: multiple sequence alignment, interactive sequence choice and visualization. Brief. Bioinform. 20, 1160–1166 (2019).
pubmed: 28968734 doi: 10.1093/bib/bbx108
Orekhov, V. Y. & Jaravine, V. A. Analysis of non-uniformly sampled spectra with multi-dimensional decomposition. Prog. Nucl. Magn. Reson. Spectrosc. 59, 271–292 (2011).
pubmed: 21920222 doi: 10.1016/j.pnmrs.2011.02.002
Delaglio, F. et al. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J. Biomol. NMR 6, 277–293 (1995).
pubmed: 8520220 doi: 10.1007/BF00197809
Vranken, W. F. et al. The CCPN data model for NMR spectroscopy: development of a software pipeline. Proteins 59, 687–696 (2005).
pubmed: 15815974 doi: 10.1002/prot.20449
Salzmann, M., Pervushin, K., Wider, G., Senn, H. & Wüthrich, K. TROSY in triple-resonance experiments: new perspectives for sequential NMR assignment of large proteins. Proc. Natl Acad. Sci. USA 95, 13585–13590 (1998).
pubmed: 9811843 pmcid: 24862 doi: 10.1073/pnas.95.23.13585
Eletsky, A., Kienhöfer, A. & Pervushin, K. TROSY NMR with partially deuterated proteins. J. Biomol. NMR 20, 177–180 (2001).
pubmed: 11495249 doi: 10.1023/A:1011265430149
Lakomek, N. A., Ying, J. & Bax, A. Measurement of
pubmed: 22689066 pmcid: 3412688 doi: 10.1007/s10858-012-9626-5
Farrow, N. A. et al. Backbone dynamics of a free and phosphopeptide-complexed Src homology 2 domain studied by 15N NMR relaxation. Biochemistry 33, 5984–6003 (1994).
pubmed: 7514039 doi: 10.1021/bi00185a040

Auteurs

Marcin J Suskiewicz (MJ)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Florian Zobel (F)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Tom E H Ogden (TEH)

MRC Laboratory of Molecular Biology, Cambridge, UK.

Pietro Fontana (P)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Antonio Ariza (A)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Ji-Chun Yang (JC)

MRC Laboratory of Molecular Biology, Cambridge, UK.

Kang Zhu (K)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

Lily Bracken (L)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

William J Hawthorne (WJ)

MRC Laboratory of Molecular Biology, Cambridge, UK.

Dragana Ahel (D)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.

David Neuhaus (D)

MRC Laboratory of Molecular Biology, Cambridge, UK.

Ivan Ahel (I)

Sir William Dunn School of Pathology, University of Oxford, Oxford, UK. ivan.ahel@path.ox.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH